Showing results (3011-3020 of 6,517) with videos related to

Sort By:
Pageof 652
Cancer Immunology, Immunotherapy : CII|March 5, 2023
Pembrolizumab near the end of life in patients with metastatic pancreatic cancer: a multi-site consecutive series to examine survival and patient treatment burdenMichael H Storandt, Nguyen Tran, Nichole Martin, et al.
Cancer Immunology, Immunotherapy : CII|February 24, 2023
Mitochondrial C1QBP is essential for T cell antitumor function by maintaining mitochondrial plasticity and metabolic fitnessHui Tian, Dafei Chai, Gang Wang, et al.
Cancer Immunology, Immunotherapy : CII|February 28, 2023
Risk factors indicating immune-related adverse events with combination chemotherapy with immune checkpoint inhibitors and platinum agents in patients with non-small cell lung cancer: a multicenter retrospective studyAiri Fujimoto, Yoshimichi Koutake, Daisuke Hisamatsu, et al.
Cancer Immunology, Immunotherapy : CII|August 26, 2022
PD-1+ mast cell enhanced by PD-1 blocking therapy associated with resistance to immunotherapyJun Li, Gang Peng, Kuikui Zhu, et al.
Cancer Immunology, Immunotherapy : CII|August 13, 2022
Characterization of anti-CD79b/CD3 bispecific antibody, a potential therapy for B cell malignanciesJie Wang, Chen Li, Kaijie He, et al.
Cancer Immunology, Immunotherapy : CII|November 10, 2022
Generation of NK cells with chimeric-switch receptors to overcome PD1-mediated inhibition in cancer immunotherapyKatharina H Susek, Ysabel A Schwietzer, Maria Karvouni, et al.
Cancer Immunology, Immunotherapy : CII|November 10, 2022
Combined pembrolizumab and bevacizumab therapy effectively inhibits non-small-cell lung cancer growth and prevents postoperative recurrence and metastasis in humanized mouse modelTianyun Qiao, Jinbo Zhao, Xiangbing Xin, et al.
Cancer Immunology, Immunotherapy : CII|March 8, 2023
Efficacy and safety of immune checkpoint inhibitors in elderly patients with primary liver cancer: a retrospective, multicenter, real-world cohort studyLushan Xiao, Yanxia Liao, Jiaren Wang, et al.
Cancer Immunology, Immunotherapy : CII|February 22, 2023
Expression of soluble CD27 in extranodal natural killer/T-cell lymphoma, nasal type: potential as a biomarker for diagnosis and CD27/CD70-targeted therapyToshihiro Nagato, Hiroki Komatsuda, Ryusuke Hayashi, et al.
Cancer Immunology, Immunotherapy : CII|February 2, 2023
Effect of genetic polymorphisms on outcomes following nivolumab for advanced renal cell carcinoma in the SNiP-RCC trialMasaki Shiota, Hideaki Miyake, Masayuki Takahashi, et al.
Pageof 652